Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation
| Autor: | Shingo Nakamoto, Shin Yasui, Shuang Wu, Shigeru Mikami, Osamu Yokosuka, Yuki Haga, Tatsuo Kanda, Masato Nakamura, Mutsumi Yamato, Makoto Arai, Hideaki Miyauchi, Hisahiro Matsubara, Reina Sasaki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cirrhosis Anemia Hepatitis C virus Case Report 030230 surgery Direct-acting antivirals medicine.disease_cause Gastroenterology Kidney transplantation 03 medical and health sciences 0302 clinical medicine Interferon Internal medicine medicine lcsh:RC799-869 Adverse effect business.industry virus diseases medicine.disease digestive system diseases Transplantation Sustained virological response Hepatocellular carcinoma lcsh:Diseases of the digestive system. Gastroenterology 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Case Reports in Gastroenterology Case Reports in Gastroenterology, Vol 10, Iss 2, Pp 248-256 (2016) |
| ISSN: | 1662-0631 |
| Popis: | Hepatitis C virus (HCV) infection leads to acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Following kidney transplantation, HCV increases the risk of graft loss and patient mortality compared with uninfected patients. The achievement of a sustained virological response with antiviral therapy improves survival and diminishes the risk of hepatic decompensation in HCV patients after a kidney transplant. It has been reported that direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of HCV in patients who are liver transplant recipients. In the present study, we investigated HCV eradication via interferon-free therapies with DAAs in two HCV patients with advanced liver fibrosis following renal transplantation. In both cases, the interferon-free regimens with DAAs were effective in eradicating HCV in the patients after kidney transplantation. No adverse events caused by interferon were identified with the exception of anemia. Interferon-free regimens with DAAs for recurrent HCV in patients following kidney transplantation are relatively safe and effective. However, attention should be focused on anemia during these treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|